Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

PHASE3CompletedINTERVENTIONAL
Enrollment

879

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
MetastasesColorectal NeoplasmsColorectal Carcinoma
Interventions
DRUG

Xaliproden (SR57746A)

oral administration

DRUG

Placebo

oral administration

DRUG

Oxaliplatin

IV administration

DRUG

5-Fluorouracil

IV administration

DRUG

Leucovorin

IV administration

Trial Locations (13)

08807

Sanofi-Aventis Administrative Office, Bridgewater

Unknown

Sanofi-Aventis Administrative Office, Buenos Aires

Sanofi-Aventis Administrative Office, Macquarie Park

Sanofi-Aventis Administrative Office, São Paulo

Sanofi-Aventis Administrative Office, Laval

Sanofi-Aventis Administrative Office, Santiago

Sanofi-Aventis Administrative Office, Berlin

Sanofi-Aventis Administrative Office, Budapest

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Warsaw

Sanofi-Aventis Administrative Office, Porto Salvo

Sanofi-Aventis Administrative Office, Barcelona

Sanofi-Aventis Administrative Office, Guildford Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY